Compare · ILMN vs KEQU
ILMN vs KEQU
Side-by-side comparison of Illumina Inc. (ILMN) and Kewaunee Scientific Corporation (KEQU): market cap, price performance, sector, and recent activity on the wire.
Summary
- ILMN operates in Health Care, while KEQU operates in Industrials - the two are in different parts of the market.
- ILMN is the larger of the two at $25.86B, about 228.1x KEQU ($113.4M).
- Over the past year, ILMN is up 105.7% and KEQU is down 11.1% - ILMN leads by 116.8 points.
- ILMN has hit the wire 24 times in the past 4 weeks while KEQU has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for KEQU).
- Company
- Illumina Inc.
- Kewaunee Scientific Corporation
- Price
- $171.04+5.25%
- $36.95+5.05%
- Market cap
- $25.86B
- $113.4M
- 1M return
- +22.71%
- +5.05%
- 1Y return
- +105.65%
- -11.10%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 24
- 0
- Recent ratings
- 25
- 0
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Kewaunee Scientific Corporation
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. It operates in two segments, Domestic and International. The company's products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Its laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture; and laminate caseworks that are used in educational, healthcare, and industrial applications. The company sells its products primarily through dealers, commissioned agents, and a national distributor, as well as through competitive bids submitted by the company and its subsidiaries in Singapore, India, and China. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.
Latest ILMN
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director King David P was granted 2,072 shares (SEC Form 4)
- Director Siegel Susan E was granted 2,072 shares, increasing direct ownership by 14% to 16,535 units (SEC Form 4)
Latest KEQU
- Director Gehl Keith M was granted 2,013 shares, increasing direct ownership by 10% to 22,409 units (SEC Form 4)
- Director Campbell John Jette was granted 2,013 shares, increasing direct ownership by 292% to 2,703 units (SEC Form 4)
- Kewaunee Scientific Corporation Appoints Jorge Santos as Vice President of International Sales, Laboratory Products Group
- SEC Form 4 filed by Pyle Margaret B
- SEC Form 10-Q filed by Kewaunee Scientific Corporation
- Kewaunee Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2026
- Kewaunee Scientific and Nu Aire Inc. to Attend analytica 2026 in Munich
- Kewaunee Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2026